The Centers for Medicare & Medicaid Services (CMS) has unveiled a groundbreaking initiative aimed at expanding access to ...

Amid a season of regulatory and scientific advances, experts reveal a culture of data hoarding among cell and gene therapy ...

Thirty-three states, the District of Columbia, and Puerto Rico will participate in CMS’ voluntary Cell and Gene Therapy (CGT) ...

New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted ...

Controlling the activity of specific genes in the laboratory through the editing of their epigenetic marks is now a reality ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...